Spark Investment Management LLC cut its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 54.6% during the third quarter, Holdings Channel reports. The institutional investor owned 86,000 shares of the biopharmaceutical company’s stock after selling 103,400 shares during the period. Spark Investment Management LLC owned approximately 0.06% of Achillion Pharmaceuticals worth $696,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ACHN. Investment Centers of America Inc. boosted its position in Achillion Pharmaceuticals by 27.7% in the second quarter. Investment Centers of America Inc. now owns 13,733 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 2,975 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Achillion Pharmaceuticals by 13.0% in the second quarter. Teacher Retirement System of Texas now owns 15,173 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 1,749 shares in the last quarter. Quantbot Technologies LP boosted its position in Achillion Pharmaceuticals by 523.6% in the third quarter. Quantbot Technologies LP now owns 15,310 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 12,855 shares in the last quarter. Trexquant Investment LP bought a new position in Achillion Pharmaceuticals during the second quarter worth about $128,000. Finally, PNC Financial Services Group Inc. boosted its position in Achillion Pharmaceuticals by 589.4% in the second quarter. PNC Financial Services Group Inc. now owns 18,351 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 15,689 shares in the last quarter. 78.45% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded down 1.18% during mid-day trading on Friday, reaching $4.20. 1,308,239 shares of the company traded hands. The firm’s market capitalization is $574.06 million. Achillion Pharmaceuticals, Inc. has a 52 week low of $3.78 and a 52 week high of $10.06. The stock’s 50 day moving average price is $4.21 and its 200 day moving average price is $6.91.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Equities analysts forecast that Achillion Pharmaceuticals, Inc. will post ($0.60) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be accessed at http://www.dailypolitical.com/2017/01/13/achillion-pharmaceuticals-inc-achn-shares-sold-by-spark-investment-management-llc.html.

A number of research analysts have issued reports on ACHN shares. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, November 7th. Jefferies Group reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Monday, September 26th. Leerink Swann reiterated a “market perform” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, November 3rd. Chardan Capital upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “neutral” rating and set a $5.00 price objective on the stock in a research note on Friday, November 4th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $10.00 price objective on shares of Achillion Pharmaceuticals in a research note on Sunday, November 6th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $9.88.

In related news, Director Jason S. Fisherman purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, December 22nd. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the director now owns 50,000 shares of the company’s stock, valued at $198,000. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.52% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

5 Day Chart for NASDAQ:ACHN

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.